Liuqing Zhu

412 total citations
22 papers, 217 citations indexed

About

Liuqing Zhu is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Liuqing Zhu has authored 22 papers receiving a total of 217 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Cancer Research and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Liuqing Zhu's work include Cancer Genomics and Diagnostics (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). Liuqing Zhu is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). Liuqing Zhu collaborates with scholars based in China, Netherlands and United Kingdom. Liuqing Zhu's co-authors include Dongqin Zhu, Guoquan Gao, Xiaoqin Li, Weiwei Qi, Ti Zhou, Yangyang Yu, Deqiang Wang, Zhijian Huang, Yang Shao and Qiuxiang Ou and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Frontiers in Immunology.

In The Last Decade

Liuqing Zhu

21 papers receiving 213 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liuqing Zhu China 10 92 72 60 48 43 22 217
Yun Zhao Chen China 8 123 1.3× 86 1.2× 65 1.1× 82 1.7× 21 0.5× 8 306
Chun Xia Liu China 8 96 1.0× 107 1.5× 59 1.0× 76 1.6× 17 0.4× 12 286
Peiqing Ma China 9 72 0.8× 76 1.1× 70 1.2× 64 1.3× 15 0.3× 14 287
Ida Russo Italy 10 44 0.5× 148 2.1× 96 1.6× 72 1.5× 23 0.5× 22 280
Francesca Ambrogio Italy 11 65 0.7× 65 0.9× 24 0.4× 50 1.0× 38 0.9× 60 268
Niloofar Khoshdel Rad Iran 9 34 0.4× 169 2.3× 22 0.4× 61 1.3× 13 0.3× 20 288
Weimin Ding China 10 100 1.1× 171 2.4× 63 1.1× 52 1.1× 28 0.7× 25 307
Shahla Bari United States 8 125 1.4× 81 1.1× 36 0.6× 44 0.9× 14 0.3× 25 262
Ke Zheng China 11 58 0.6× 160 2.2× 76 1.3× 19 0.4× 11 0.3× 18 275
Rohini Sharma India 8 43 0.5× 79 1.1× 35 0.6× 26 0.5× 20 0.5× 18 243

Countries citing papers authored by Liuqing Zhu

Since Specialization
Citations

This map shows the geographic impact of Liuqing Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liuqing Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liuqing Zhu more than expected).

Fields of papers citing papers by Liuqing Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liuqing Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liuqing Zhu. The network helps show where Liuqing Zhu may publish in the future.

Co-authorship network of co-authors of Liuqing Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Liuqing Zhu. A scholar is included among the top collaborators of Liuqing Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liuqing Zhu. Liuqing Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liang, Jin‐Hua, Wei Hua, Hua Yin, et al.. (2025). Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study. Cell Communication and Signaling. 23(1). 441–441.
2.
Du, Yu, Ming Sun, Shanshan Qi, et al.. (2024). Molecular characterization and biomarker identification in pediatric B-cell acute lymphoblastic leukemia.. Journal of Clinical Oncology. 42(16_suppl). 6524–6524. 1 indexed citations
3.
Liang, Jin‐Hua, Yifan Wu, Yue Li, et al.. (2024). Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma. Leukemia. 38(7). 1541–1552. 6 indexed citations
4.
Li, Yang, Mengchen Zhu, Xiaotian Zhao, et al.. (2024). The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas. Future Oncology. 20(38). 3107–3117. 1 indexed citations
5.
Shi, Min, et al.. (2024). Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application. Molecular Cancer. 23(1). 36–36. 8 indexed citations
6.
Sun, Ming, Shanshan Qi, Chenxuan Wang, et al.. (2024). Molecular characterization and biomarker identification in paediatric B‐cell acute lymphoblastic leukaemia. Journal of Cellular and Molecular Medicine. 28(19). e70126–e70126. 3 indexed citations
7.
Xing, Ai‐Yan, et al.. (2022). Clinicopathological Characteristics and Molecular Phenotypes of Primary Hepatic Lymphoma. Frontiers in Oncology. 12. 906245–906245. 5 indexed citations
8.
Ding, Ying, Sha Zhao, Mingna Li, et al.. (2022). The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification. BMC Cancer. 22(1). 186–186. 13 indexed citations
9.
Zhou, Xin, Peng Shao, Liuqing Zhu, et al.. (2022). FBXW7 and Its Downstream NOTCH Pathway Could be Potential Indicators of Organ-Free Metastasis in Colorectal Cancer. Frontiers in Oncology. 11. 783564–783564. 19 indexed citations
10.
Shan, Benjie, Xinghua Han, Xiaotian Zhao, et al.. (2022). Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer. Frontiers in Oncology. 11. 784985–784985. 19 indexed citations
11.
Xia, Qiuyuan, Qiu Rao, Yang Shao, et al.. (2021). Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases. Diagnostic Pathology. 16(1). 114–114. 9 indexed citations
12.
Wang, Deqiang, Ning Wang, Xiaoqin Li, et al.. (2021). Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia. Gastric Cancer. 24(4). 823–834. 26 indexed citations
13.
Li, Xiaoqin, Dongqiang Zeng, Xiaofeng Chen, et al.. (2021). Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer. Frontiers in Immunology. 11. 609337–609337. 17 indexed citations
14.
Wang, Xiaoxiao, Yan Gao, Shanshan Yu, et al.. (2021). Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma. Blood. 138(Supplement 1). 2481–2481. 2 indexed citations
15.
Zhu, Yingying, Ran Jia, Yang Shao, et al.. (2020). Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report. Frontiers in Oncology. 10. 1259–1259. 4 indexed citations
16.
Chen, Xiaofeng, Hao Wu, Xiaofeng Wu, et al.. (2020). Biomarker exploration for SHR-1210 plus GEMOX as first-line treatment in advanced biliary tract cancer.. Journal of Clinical Oncology. 38(4_suppl). 536–536. 2 indexed citations
17.
Li, Cen, Zhijian Huang, Liuqing Zhu, et al.. (2019). The contrary intracellular and extracellular functions of PEDF in HCC development. Cell Death and Disease. 10(10). 742–742. 18 indexed citations
18.
Chen, Xiaofeng, Xiaofeng Wu, Hao Wu, et al.. (2019). SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: Results from a single-arm exploratory study.. Journal of Clinical Oncology. 37(15_suppl). 4092–4092. 8 indexed citations
19.
Mao, Yuling, Liuqing Zhu, Zhijian Huang, et al.. (2019). Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer. Endocrine Related Cancer. 27(1). 23–39. 21 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yun Zhao Chen Breakdown of academic impact, for papers by Chun Xia Liu Breakdown of academic impact, for papers by Peiqing Ma Breakdown of academic impact, for papers by Ida Russo Breakdown of academic impact, for papers by Francesca Ambrogio Breakdown of academic impact, for papers by Niloofar Khoshdel Rad Breakdown of academic impact, for papers by Weimin Ding Breakdown of academic impact, for papers by Shahla Bari Breakdown of academic impact, for papers by Ke Zheng Breakdown of academic impact, for papers by Rohini Sharma
Rankless by CCL
2026